As of Q2 2026 Albany reported cash of about $77 million, total debt around $451 million and net debt near $373 million, with net leverage at 1.71x and access to an $800 million unsecured credit facility.
The company has maintained dividends, selectively repurchased stock under a $250 million authorization approved in 2025, and continues to invest in R&D and capex while staying within conservative leverage.
Working capital swings reduced H1‑2026 operating cash flow to about $3 million, but our TTM build remains positive and the balance sheet can absorb variability. Contingent liabilities include legacy asbestos litigation and aerospace program exposures, both monitored in filings.







